Sequenom Inc (SQNM) 3.62 $SQNM
Sequenom to Continue to Lead the US NIPT Market by 2018
M2 - Tue Feb 03, 3:25AM CST
The market for non-invasive prenatal diagnostics tests in the US is currently dominated by Sequenom as it got the first mover advantage in the industry. With around 50% market share in terms of volume, Sequenom boasts of having effective marketing strategies that seek to encourage US physicians to recommend its MaterniT21 plus test. In terms of value, Sequenom will remain the market leader in 2018 as well accounting for over 45% of the total market share.
SQNM: 3.62 (unch)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Cypher Genomics and Sequenom Announce Development Agreement
PR Newswire - Thu Jan 22, 6:00AM CST
Cypher Genomics, Inc., the leading genome informatics company, and Sequenom, Inc. (NASDAQ: SQNM), the leading molecular diagnostics company, today announced a development agreement for next generation noninvasive prenatal tests (NIPT). Through this agreement, Sequenom will utilize Cypher's genome interpretation technology, called Mantis(TM), to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood. Often not detected until after birth, sub-chromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with significant risks of morbidity and mortality.
SQNM: 3.62 (unch)
Sequenom's VisibiliT Has A Huge Opportunity In Replacing The First Trimester Screen
Doug Van Cuyk - at Seeking Alpha - Wed Jan 21, 11:56AM CST
SQNM: 3.62 (unch)
The Liquid Biopsy Will Boost Revenue For Sequenom And Illumina
Doug Van Cuyk - at Seeking Alpha - Thu Jan 15, 10:36AM CST
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81), EXAS: 25.56 (-0.54)
Research and Markets: Global Prenatal and Newborn Genetic Testing Market 2015-2019 with Agilent Technologies, Bio-Rad Laboratories, Illumina & Sequenom Dominating
Business Wire - Wed Jan 14, 2:40PM CST
Research and Markets (http://www.researchandmarkets.com/research/h7vwq8/global_prenatal) has announced the addition of the "Global Prenatal and Newborn Genetic Testing Market 2015-2019" report to their offering.
SQNM: 3.62 (unch), A: 40.15 (+0.13)
Global Prenatal and Newborn Genetic Testing Market 2015-2019 with Agilent Technologies, Bio-Rad Laboratories, Illumina & Sequenom Dominating
M2 - Wed Jan 14, 11:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/wbgb7s/global_prenatal) has announced the addition of the "Global Prenatal and Newborn Genetic Testing Market 2015-2019" report to their offering. The Global Prenatal and Newborn Genetic Testing market to grow at a CAGR of 31.91% over the period 2014-2019 Prenatal and newborn genetic testing involves genetic testing before and after birth. Prenatal testing helps detect changes in the fetus before birth. It can reduce a couple's uncertainty or help them decide whether to abort a pregnancy in case of conditions such as Down syndrome, trisomy 18, or an open neural tube defect. The procedure includes two blood tests: one in the first trimester and the next in the second trimester. On the other hand, newborn genetic testing is done just after birth to identify genetic disorders. One key trend emerging in this market is the launch of new tests. For instance, in 2014, Laboratory Corporation of America Holdings launched the informaSeq Prenatal Test. In the same year, Sequenom launched the VisibiliT laboratory-developed test in international markets. According to the report, one of the major drivers of the market is the growing incidence of fetal health-related abnormalities such as Down syndrome, Edward syndrome, neural tube defects, sickle cell anemia, thalassemia, Tay-Sachs disease, spina bifida, cystic fibrosis, cleft palate, muscular dystrophy, and fragile X syndrome. Further, the report states that a decrease in fertility rates worldwide is one of the main challenges that the market faces. This has led to a decline in the number of pregnancies, resulting in a reduction in the demand for prenatal and newborn testing The Global Prenatal and Newborn Genetic Testing market can be divided into two segments: - Diagnostic Techniques - Screening Methods Key Vendors - Agilent Technologies - Bio-Rad Laboratories - Illumina - Sequenom Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Technology - Prenatal Screening Tests - Causes and Risk Factors - Genetic Disorders before Birth - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/wb...l_prenatal
SQNM: 3.62 (unch), A: 40.15 (+0.13), LH: 116.90 (+0.06)
Illumina, An Explosive Opportunity, Currently Slightly Overpriced
Doug Van Cuyk - at Seeking Alpha - Tue Jan 13, 7:16AM CST
SQNM: 3.62 (unch), TMO: 127.61 (+0.78), ILMN: 198.54 (+1.81)
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom
PR Newswire - Mon Jan 12, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), VIVUS Inc. (NASDAQ: VVUS), Actavis PLC (NYSE: ACT), Covance Inc. (NYSE: CVD), and Sequenom Inc. (NASDAQ: SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, January 09, 2015, the NASDAQ Composite ended at 4,704.07, down 0.68%, the Dow Jones Industrial Average declined 0.95%, to finish the day at 17,737.37, and the S&P 500 closed at 2,044.81, down 0.84%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 813.23, down 0.81%, while the index has surged 11.61% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 99.62 (+1.18), SQNM: 3.62 (unch), ACT: 285.37 (+3.71), VVUS: 2.68 (+0.13), CVD: 107.08 (+0.05)
Why Sequenom, Inc. Stock Scorched 23% Higher in December
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 07, 10:03AM CST
What: Shares of Sequenom , a life sciences company focused on developing genomic and genetic analysis solutions and diagnostics, soared by 23% in December, based on data from S&P Capital IQ , after settling a long-standing legal dispute with...
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81)
Sequenom, Inc. Announces Participation At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Tue Jan 06, 6:00AM CST
Sequenom, Inc. (NASDAQ: SQNM), a leading molecular diagnostics company, today announced the Company's participation at the 2015 J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel, in San Francisco, CA on January 12-15, 2015.
SQNM: 3.62 (unch), JPM: 59.67 (+0.10)
Commit To Buy Sequenom At $3, Earn 8.3% Using Options
at The Street - Wed Dec 31, 10:45AM CST
Investors considering a purchase of Sequenom Inc shares, but tentative about paying the going market price of $3.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
SQNM: 3.62 (unch)
Quarterly Report Card: Comprehensive Research on Remy International, RF Industries, Roka Bioscience, Schmitt Industries and Sequenom
PR Newswire - Mon Dec 22, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Remy International (NASDAQ: REMY), RF Industries (NASDAQ: RFIL), Roka Bioscience (NASDAQ: ROKA), Schmitt Industries (NASDAQ: SMIT), and Sequenom (NASDAQ: SQNM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SMIT: 2.73 (unch), ROKA: 4.04 (+0.01), SQNM: 3.62 (unch), RFIL: 4.13 (-0.02), REMY: 22.59 (-0.22)
Hawaiian Electric and Taser are big market movers
AP - Thu Dec 04, 3:35PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 203.77 (+0.89), HE: 33.14 (-0.22), PLUG: 3.15 (unch), CLV: 6.86 (+0.16), CLF: 7.00 (+0.35), BKS: 24.51 (+0.07), ARO: 3.63 (+0.04), RAD: 8.34 (+0.25), CARB: 14.96 (+0.07), SQNM: 3.62 (unch), ENB.TO: 61.52 (-0.46), RIG: 19.05 (+0.42), IDRA: 4.10 (-0.14), ANF: 26.08 (+0.85), ENB: 49.37 (-0.22), TASR: 26.96 (-0.42), AVGO: 110.15 (+0.45), PBYI: 205.26 (+2.75)
Is Sequenom Next?
Doug Van Cuyk - at Seeking Alpha - Thu Dec 04, 1:37PM CST
SQNM: 3.62 (unch)
Most active Nasdaq-traded stocks
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 31.85 (-0.09), SQNM: 3.62 (unch), PLUG: 3.15 (unch), FB: 75.74 (-0.49), AMAT: 24.12 (-0.02), JBLU: 16.83 (+0.09), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), RFMD: 16.59 (-0.35)
Sequenom (SQNM) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:08AM CST
Sequenom (SQNM) Shares March Higher, Can It Continue?
SQNM: 3.62 (unch)
Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 6:21AM CST
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise by nearly 24% on the day.
BIIB: 391.66 (-0.45), SQNM: 3.62 (unch), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Stocks Close Higher, Helped by Continued Strength in Economy
at The Street - Wed Dec 03, 3:19PM CST
The S&P 500 inched to another record high Wednesday after the release of the Federal Reserve's Beige Book showed the economy is still gaining strength.
GIII: 103.56 (+0.65), HAL: 44.19 (+1.42), BOBE: 56.41 (-0.68), ILMN: 198.54 (+1.81), SLB: 88.38 (+2.42), SQNM: 3.62 (unch), JCP: 8.05 (+0.14), BP: 41.93 (+0.59), PBYI: 205.26 (+2.75), XLE: 82.04 (+1.70)
Why Sequenom, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 2:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sequenom , a developer of genetic analysis...
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81)
Sequenom to Continue to Lead the US NIPT Market by 2018
M2 - Tue Feb 03, 3:25AM CST
The market for non-invasive prenatal diagnostics tests in the US is currently dominated by Sequenom as it got the first mover advantage in the industry. With around 50% market share in terms of volume, Sequenom boasts of having effective marketing strategies that seek to encourage US physicians to recommend its MaterniT21 plus test. In terms of value, Sequenom will remain the market leader in 2018 as well accounting for over 45% of the total market share.
SQNM: 3.62 (unch)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Cypher Genomics and Sequenom Announce Development Agreement
PR Newswire - Thu Jan 22, 6:00AM CST
Cypher Genomics, Inc., the leading genome informatics company, and Sequenom, Inc. (NASDAQ: SQNM), the leading molecular diagnostics company, today announced a development agreement for next generation noninvasive prenatal tests (NIPT). Through this agreement, Sequenom will utilize Cypher's genome interpretation technology, called Mantis(TM), to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood. Often not detected until after birth, sub-chromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with significant risks of morbidity and mortality.
SQNM: 3.62 (unch)
Sequenom's VisibiliT Has A Huge Opportunity In Replacing The First Trimester Screen
Doug Van Cuyk - at Seeking Alpha - Wed Jan 21, 11:56AM CST
SQNM: 3.62 (unch)
The Liquid Biopsy Will Boost Revenue For Sequenom And Illumina
Doug Van Cuyk - at Seeking Alpha - Thu Jan 15, 10:36AM CST
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81), EXAS: 25.56 (-0.54)
Research and Markets: Global Prenatal and Newborn Genetic Testing Market 2015-2019 with Agilent Technologies, Bio-Rad Laboratories, Illumina & Sequenom Dominating
Business Wire - Wed Jan 14, 2:40PM CST
Research and Markets (http://www.researchandmarkets.com/research/h7vwq8/global_prenatal) has announced the addition of the "Global Prenatal and Newborn Genetic Testing Market 2015-2019" report to their offering.
SQNM: 3.62 (unch), A: 40.15 (+0.13)
Global Prenatal and Newborn Genetic Testing Market 2015-2019 with Agilent Technologies, Bio-Rad Laboratories, Illumina & Sequenom Dominating
M2 - Wed Jan 14, 11:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/wbgb7s/global_prenatal) has announced the addition of the "Global Prenatal and Newborn Genetic Testing Market 2015-2019" report to their offering. The Global Prenatal and Newborn Genetic Testing market to grow at a CAGR of 31.91% over the period 2014-2019 Prenatal and newborn genetic testing involves genetic testing before and after birth. Prenatal testing helps detect changes in the fetus before birth. It can reduce a couple's uncertainty or help them decide whether to abort a pregnancy in case of conditions such as Down syndrome, trisomy 18, or an open neural tube defect. The procedure includes two blood tests: one in the first trimester and the next in the second trimester. On the other hand, newborn genetic testing is done just after birth to identify genetic disorders. One key trend emerging in this market is the launch of new tests. For instance, in 2014, Laboratory Corporation of America Holdings launched the informaSeq Prenatal Test. In the same year, Sequenom launched the VisibiliT laboratory-developed test in international markets. According to the report, one of the major drivers of the market is the growing incidence of fetal health-related abnormalities such as Down syndrome, Edward syndrome, neural tube defects, sickle cell anemia, thalassemia, Tay-Sachs disease, spina bifida, cystic fibrosis, cleft palate, muscular dystrophy, and fragile X syndrome. Further, the report states that a decrease in fertility rates worldwide is one of the main challenges that the market faces. This has led to a decline in the number of pregnancies, resulting in a reduction in the demand for prenatal and newborn testing The Global Prenatal and Newborn Genetic Testing market can be divided into two segments: - Diagnostic Techniques - Screening Methods Key Vendors - Agilent Technologies - Bio-Rad Laboratories - Illumina - Sequenom Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Technology - Prenatal Screening Tests - Causes and Risk Factors - Genetic Disorders before Birth - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/wb...l_prenatal
SQNM: 3.62 (unch), A: 40.15 (+0.13), LH: 116.90 (+0.06)
Illumina, An Explosive Opportunity, Currently Slightly Overpriced
Doug Van Cuyk - at Seeking Alpha - Tue Jan 13, 7:16AM CST
SQNM: 3.62 (unch), TMO: 127.61 (+0.78), ILMN: 198.54 (+1.81)
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom
PR Newswire - Mon Jan 12, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), VIVUS Inc. (NASDAQ: VVUS), Actavis PLC (NYSE: ACT), Covance Inc. (NYSE: CVD), and Sequenom Inc. (NASDAQ: SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, January 09, 2015, the NASDAQ Composite ended at 4,704.07, down 0.68%, the Dow Jones Industrial Average declined 0.95%, to finish the day at 17,737.37, and the S&P 500 closed at 2,044.81, down 0.84%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 813.23, down 0.81%, while the index has surged 11.61% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 99.62 (+1.18), SQNM: 3.62 (unch), ACT: 285.37 (+3.71), VVUS: 2.68 (+0.13), CVD: 107.08 (+0.05)
Why Sequenom, Inc. Stock Scorched 23% Higher in December
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 07, 10:03AM CST
What: Shares of Sequenom , a life sciences company focused on developing genomic and genetic analysis solutions and diagnostics, soared by 23% in December, based on data from S&P Capital IQ , after settling a long-standing legal dispute with...
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81)
Sequenom, Inc. Announces Participation At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Tue Jan 06, 6:00AM CST
Sequenom, Inc. (NASDAQ: SQNM), a leading molecular diagnostics company, today announced the Company's participation at the 2015 J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel, in San Francisco, CA on January 12-15, 2015.
SQNM: 3.62 (unch), JPM: 59.67 (+0.10)
Commit To Buy Sequenom At $3, Earn 8.3% Using Options
at The Street - Wed Dec 31, 10:45AM CST
Investors considering a purchase of Sequenom Inc shares, but tentative about paying the going market price of $3.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
SQNM: 3.62 (unch)
Quarterly Report Card: Comprehensive Research on Remy International, RF Industries, Roka Bioscience, Schmitt Industries and Sequenom
PR Newswire - Mon Dec 22, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Remy International (NASDAQ: REMY), RF Industries (NASDAQ: RFIL), Roka Bioscience (NASDAQ: ROKA), Schmitt Industries (NASDAQ: SMIT), and Sequenom (NASDAQ: SQNM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SMIT: 2.73 (unch), ROKA: 4.04 (+0.01), SQNM: 3.62 (unch), RFIL: 4.13 (-0.02), REMY: 22.59 (-0.22)
Hawaiian Electric and Taser are big market movers
AP - Thu Dec 04, 3:35PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 203.77 (+0.89), HE: 33.14 (-0.22), PLUG: 3.15 (unch), CLV: 6.86 (+0.16), CLF: 7.00 (+0.35), BKS: 24.51 (+0.07), ARO: 3.63 (+0.04), RAD: 8.34 (+0.25), CARB: 14.96 (+0.07), SQNM: 3.62 (unch), ENB.TO: 61.52 (-0.46), RIG: 19.05 (+0.42), IDRA: 4.10 (-0.14), ANF: 26.08 (+0.85), ENB: 49.37 (-0.22), TASR: 26.96 (-0.42), AVGO: 110.15 (+0.45), PBYI: 205.26 (+2.75)
Is Sequenom Next?
Doug Van Cuyk - at Seeking Alpha - Thu Dec 04, 1:37PM CST
SQNM: 3.62 (unch)
Most active Nasdaq-traded stocks
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 31.85 (-0.09), SQNM: 3.62 (unch), PLUG: 3.15 (unch), FB: 75.74 (-0.49), AMAT: 24.12 (-0.02), JBLU: 16.83 (+0.09), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), RFMD: 16.59 (-0.35)
Sequenom (SQNM) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:08AM CST
Sequenom (SQNM) Shares March Higher, Can It Continue?
SQNM: 3.62 (unch)
Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 6:21AM CST
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise by nearly 24% on the day.
BIIB: 391.66 (-0.45), SQNM: 3.62 (unch), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Stocks Close Higher, Helped by Continued Strength in Economy
at The Street - Wed Dec 03, 3:19PM CST
The S&P 500 inched to another record high Wednesday after the release of the Federal Reserve's Beige Book showed the economy is still gaining strength.
GIII: 103.56 (+0.65), HAL: 44.19 (+1.42), BOBE: 56.41 (-0.68), ILMN: 198.54 (+1.81), SLB: 88.38 (+2.42), SQNM: 3.62 (unch), JCP: 8.05 (+0.14), BP: 41.93 (+0.59), PBYI: 205.26 (+2.75), XLE: 82.04 (+1.70)
Why Sequenom, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 2:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sequenom , a developer of genetic analysis...
SQNM: 3.62 (unch), ILMN: 198.54 (+1.81)
